Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

775 recalls, newest first

Class II · Moderate risk

Sunitinib Malate Capsules

Failed Moisture Limits: Water (moisture) content above the approved product specifications.

Terminated Failed specification Teva Pharmaceuticals USA Inc NDC 0093-8199-28 D-0913-2023
Class I · High risk

Albuterol Sulfate Inhalation Aerosol

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Terminated Packaging defect Cipla USA, Inc. NDC 69097-142-60 D-0938-2023
Class III · Low risk

Amlodipine Besylate Tablets

Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-721-03 D-0899-2023
Class I · High risk

Tydemy

Failed Stability Specification and Failed Impurities/Degradation Specifications: out of specification for inactive content ascorbic acid and MTHFRC-7impurity test

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-904-71 D-1081-2023
Class II · Moderate risk

Tizanidine Tablets

Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.

Terminated Dissolution failure Amerisource Health Services LLC NDC 68084-645-01 D-0892-2023
Class II · Moderate risk

Endometrin

cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

Terminated Microbial contamination Ferring Pharmaceuticals Inc NDC 55566-6500-03 D-0879-2023
Class III · Low risk

Lysteda (tranexamic acid)

Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Terminated Impurity / degradation Amring Pharmaceuticals Inc NDC 69918-301-30 D-0871-2023

Recalls by year